Company news

CareDx, Inc. news in 2026

CareDx, Inc.'s news releases, calls and decks from 2026, newest first.

View company

CareDx Announces Third KOAR Analysis Published in Transplantation

November 3, 2026

CareDx Announces Third Quarter 2026 Financial Results

October 29, 2026

CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026

October 22, 2026

CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026

October 15, 2026

CareDx Announces Second Quarter 2026 Financial Results

July 29, 2026

CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

July 16, 2026

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

July 16, 2026

CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

July 1, 2026

CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific

June 30, 2026

CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress

June 18, 2026

CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology

June 16, 2026

CareDx Announces Dismissal of 2021 Qui Tam Suit

May 11, 2026

CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing

April 28, 2026

CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting

April 20, 2026

CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing

April 20, 2026

CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results

April 14, 2026

CareDx to Report First Quarter 2026 Financial Results on April 28, 2026

April 14, 2026

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

March 4, 2026

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

February 24, 2026

CareDx Announces Fourth Quarter and Full Year 2025 Financial Results

February 23, 2026

CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

February 17, 2026

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

February 12, 2026

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 10, 2026

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

February 3, 2026

CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 27, 2026

CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

January 12, 2026

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

January 7, 2026

Calls in 2026

Decks in 2026